Skip to main content
SpringerLink
Log in

Entwicklung der Therapie des Ovarialkarzinoms

  • Conference paper
Book cover 52. Kongreß der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe

  • 75 Accesses

Zusammenfassung

Die Kombination von Cisplatin und Paclitaxel erwies sich in zwei randomisierten Pha- se-III-Studien gegenüber dem älteren Standard (Platin plus einem Alkylans) überlegen [1,2] und wurde deshalb als neuer Standard in der Primärtherapie des fortgeschrittenen Ovarialkarzinoms akzeptiert. Die besseren Resultate wurden mit mehr Toxizität, speziell Neurotoxizität, erkauft. Die Substitution von Cisplatin durch Carboplatin sollte den Effektivitätsvorteil dieser neuen Kombination mit einem günstigeren Toxizitätsprofil verbinden. 7 Phase-I/II-Studien entwickelten eine Kombination von Carboplatin-Paclitaxel [3,4, 5,6,7,8,9]; die Erfahrungen dieser Studien führten zur Initiierung von 3 Pha- se-III-Studien zum Vergleich der Cisplatin-Paclitaxel-Standardtherapie mit einer Carbo- platin-Paclitaxel-Kombination. Die Interimsanalyse der AGO-Studie OVAR-3 [10] wird hier vorgestellt. Zwischen 10/95 und 11/97 wurden 798 Patientinnen in diese prospektiv randomisierte Studie eingeschlossen. Die Therapiearme bestanden aus Carboplatin dosiert nach AUC 6 [11] plus Paclitaxel 185 mg/m2 (Arm A) und Cisplatin 75 mg/m2 plus Paclitaxel 185 mg/m2 (Arm B). Paclitaxel wurde als 3-Stunden-Infusion verabreicht, die Prämedikation bestand aus einer Einmaldosis von Dexamethason, einem 5-HT3-, einem H1 und einem H2-Antagonisten. In beiden Armen wurden 6 Zyklen alle 3 Wochen verabreicht. 790 der 798 rekrutierten Patientinnen erfüllten die Einschlußkriterien mit einem Ovarialkarzinom FIGO IIB-IV und einem Intervall ≤ 6 Wochen zur Primäroperation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1 – 6

    Article  PubMed  CAS  Google Scholar 

  2. Stuart G, Bertelsen K, Mangioni C et al. (1998) Updated analysis shows highly significant improved overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC, NOCOVA, NCIC CTG and Scottish intergroup trial. Proc Am Soc Clin Oncol 17, abstr 1394

    Google Scholar 

  3. du Bois A, Lück HJ, Bauknecht T et al. (1997) Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Annal Oncol 8: 355 – 361

    Article  Google Scholar 

  4. Bookmann MA, McGuire III WP, Kilpatrick D et al. (1996) Carboplatin and paclitaxel in ovarian Carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14: 1895 – 1902

    Google Scholar 

  5. Huizing MT, van Warmerdam LJC, Rösing H et al. (1997) Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15: 1953 – 1964

    PubMed  CAS  Google Scholar 

  6. ten Bokkel Huinink WW, van Warmerdam LJC, Heimerhorst Tjet al. (1997) Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. Annal Oncol 8: 351 – 354

    Article  Google Scholar 

  7. Bolis G, Scarfone G, Zanaboni F et al. (1997) A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Eur J Cancer 33: 592 – 595

    Article  PubMed  CAS  Google Scholar 

  8. Siddiqui N, Boddy AV, Thomas HD, Robson L, Lind MJ, Calvert AH (1997) A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer 75: 287 – 294

    Article  PubMed  CAS  Google Scholar 

  9. Lhomme C, Kerbrat P, Lejeune C et al. (1996) Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study. Semin Oncol 23 (suppl. 12): 48 – 54

    PubMed  CAS  Google Scholar 

  10. du Bois A, Richter B, Warm M et al. (1998) Cisplatin/paclitaxel vs carboplatin/paclitaxel as lst-line treatment in ovarian cancer. Proc Am Soc Clin Oncol 17, abstr 1395

    Google Scholar 

  11. Calvert AH, Newell DR, Gumbrell LA (1989) Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 17: 1748 – 1756

    Google Scholar 

  12. McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compa- red with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1 – 6

    Article  PubMed  CAS  Google Scholar 

  13. du Bois A, Richter B, Warm M et al. (1998) Cisplatin/paclitaxel vs carboplatin/paclitaxel as lst-line treatment in ovarian cancer. Proc Am Soc Clin Oncol 17, abstr 1395

    Google Scholar 

  14. Ovarian Cancer Meta-Analysis Project (1991) Cyclophosphamide, doxorubicin, and cisplatin chemotherapy for ovarian Carcinoma: a meta-analysis. J Clin Oncol 9: 1668 – 1674

    Google Scholar 

  15. A’Hern RP, Gore ME (1995) Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 45: 726 – 732

    Google Scholar 

  16. Fanning J, Bennett TZ, Hilgers RD (1992) Metaanalysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian Carcinoma. Obstet Gynecol 80: 954 – 960

    PubMed  CAS  Google Scholar 

  17. Naumann RW, Alvarez RD, Omura GA et al. (1997) A phase I study of paclitaxel and cisplatin with escalating doses of doxorubicin in patients with previously untreated epithelial ovarian cancer. Proc Am Soc Clin Oncol 16, abstr 1333

    Google Scholar 

  18. Hill ME, Moore J, Johnston SR et al. (1997) G-CAT (G-CSF, cis/carboplatin, Adriamycin® and Taxol®) for advanced ovarian cancer: active but toxic. Proc Am Soc Clin Oncol 16, abstr 1321

    Google Scholar 

  19. Dimipoulos MA, Papadimitriou CA, Akrivos T et al. (1997) Paclitaxel, cisplatin and epirubicin with G-CSF for newly diagnosed patients with epithelial ovarian cancer. Proc Am Soc Clin Oncol 16, abstr 1313

    Google Scholar 

  20. Greggi S, Benedetti-Panici P, Amoroso M et al. (1998) Phase I trial of dose-escalated epirubicin (E), and paclitaxel (T), in combination with cisplatin (P) + G-CSF in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 17, abstr 1411

    Google Scholar 

  21. Brunetti I, Tanganelli L, Romanini A et al. (1998) Epidoxorubicin (EPIDOX), carboplatin (CBDCA) and paclitaxel (PTX) in advanced epithelial ovarian cancer (AEOC). Proc Am Soc Clin Oncol 17, abstr 1350

    Google Scholar 

  22. Kristensen GB, Trope C (1998) Carboplatinum, paclitaxel, and epirubicin combination as first-line chemotherapy in ovarian cancer. Gynecol Oncol 68: 117, abstr 184

    Google Scholar 

Download references

Author information

Authors
  1. A. du Bois
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. J. Lück
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Meier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Möbus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Warm
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W. Schröder
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Th. Bauknecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Olbricht
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. U. Nitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ch. Jackisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D. Bunjes
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. F. Opri
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. W. E. Berdel
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. D. Wallwiener
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. R. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. W. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. C. von Schilling
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. C. Thomssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. D. K. Hossfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. N. Frickhofen
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. R. Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. J. Quaas
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. J. Pfisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. H. G. Meerpohl
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

für die AGO-Studiengruppe Ovarialkarzinom

Editor information

Editors and Affiliations

  1. Frauenklinik — Klinikum St. Marien, Universität Erlangen-Nürnberg, 92224, Amberg, Germany

    Dietrich Berg

  2. Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Universität zu Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany

    Klaus Diedrich

  3. Gynäkologische Abteilung, Albert-Schweitzer- Krankenhaus, Sturmbäume 8–10, 37154, Northeim, Germany

    Rüdiger Rauskolb

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

du Bois, A. et al. (2000). Entwicklung der Therapie des Ovarialkarzinoms. In: Berg, D., Diedrich, K., Rauskolb, R. (eds) 52. Kongreß der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59688-9_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59688-9_26

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64085-8

  • Online ISBN: 978-3-642-59688-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation